NEW YORK (GenomeWeb) – Opko Health reported after the close of the market Monday that its third quarter revenues jumped 108 percent compared to Q3 2015, driven primarily by revenues from clinical lab BioReference Laboratories, which it acquired in August 2015.

For the three-month period ended Sept. 30, Opko's revenues rose to $298.0 million from $143.0 million a year ago, missing Wall Street analysts' consensus estimate for revenues of $322.0 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.